Maximise Adoption. Enhance Patient Outcomes. Accelerate Success.
iSWITCHED empowers pharmaceutical companies to bridge the gap between clinical potential and real-world adoption of safer antipsychotics through evidence-based protocols for switching, enhanced clinician education, and real-world data insights, ultimately improving patient outcomes and accelerating market access.
Bridge Innovation and Practice to Advance Safer Antipsychotic Adoption
At iSWITCHED, we help pharmaceutical companies bridge the gap between the clinical potential of newer, safer antipsychotics and their adoption in real-world practice. Despite accounting for only approximately 18.6% of the $16.14 billion global antipsychotic market, newer antipsychotics like lurasidone, aripiprazole, and cariprazine offer significant safety and efficacy advantages over older, higher-risk ones.
Our innovative digital switching tool equips clinicians with the tools they need to confidently switch patients to these medications, overcoming hesitation and knowledge gaps. By fostering clinician confidence and generating real-world evidence, iSWITCHED accelerates adoption, improves patient outcomes, and enhances the market impact of safer antipsychotics.
The Problem
Pharmaceutical companies face persistent challenges in achieving the adoption of newer antipsychotics, despite their benefits:
Clinician Hesitation: Fear of relapse and limited evidence-based protocols for switching make clinicians cautious about prescribing newer antipsychotics.
Knowledge Gaps: Many clinicians lack familiarity with newer antipsychotics, reducing confidence in prescribing drugs (e.g. lurasidone, aripiprazole, cariprazine, etc.).
Market Competition: Newer antipsychotics represent less than 20% of the global market, highlighting an untapped opportunity for broader adoption.
Regulatory Challenges: A lack of clean, reliable real-world evidence (RWE) on switching outcomes complicates regulatory submissions and slows market access.
Patient Non-Adherence: Without tools for shared decision-making, patients are often resistant to medication changes, further slowing adoption rates.
Our Solution
iSWITCHED empowers pharmaceutical companies to drive the adoption of newer antipsychotics by addressing clinician and patient barriers with the following tools: